An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection.

An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection.

HSV-1 causes 50% of first-time genital herpes infections in resource-rich countries and affects 190 million people worldwide. A prophylactic herpes vaccine is needed to protect against genital infections by both HSV-1 and HSV-2. Previously our laboratory developed a trivalent vaccine that targets gl...

Full description

Bibliographic Details
Main Authors: Kevin P Egan, Lauren M Hook, Alexis Naughton, Norbert Pardi, Sita Awasthi, Gary H Cohen, Drew Weissman, Harvey M Friedman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-07-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1008795

Internet

https://doi.org/10.1371/journal.ppat.1008795

Similar Items